Trypanosomatid parasites causing neglected diseases

Current Medicinal Chemistry

Volumn 17, Issue 15, 2010, Pages 1594-1617

  Nussbaum, K ^a   Honek, J ^a   Cadmus, C M C v C ^a   Efferth, T ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

American trypanosomiasis; Chemotherapy; Human african trypanosomiasis; Leishmania infantum; Neglected disease; Trypanosoma brucei; Trypanosoma cruzi; Visceral leishmaniasis

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 2,3 DIDEHYDRO 2 DESOXY N ACETYLNEURAMINIC ACID; 2,3 DIFLUOROSIALIC ACID; 8 CYANODIHYDROBERBERINE; ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BENZNIDAZOLE; BERBERINE DERIVATIVE; CANADINE; CYSTEINE PROTEINASE INHIBITOR; DNA VACCINE; EFLORNITHINE; GAMMA INTERFERON; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; MORPHOLINECARBONYL PHENYLALANIN HOMOPHENYLALANINE VINYL SULPHONE PHENYL; N METHYL PIPERAZINEPHENYLALANINE HOMOPHENYLALANINE VINYL SULPHONE PHENYL; N METHYL TETRA HYDROBERBERINE IODINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; POSACONAZOLE; RAVUCONAZOLE; SIALIDASE INHIBITOR; STIBOGLUCONATE SODIUM; SURAMIN; TRYPANOSOMA CRUZI VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AFRICAN TRYPANOSOMIASIS; AGRANULOCYTOSIS; ANAPHYLACTIC SHOCK; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; BRAIN TOXICITY; CARDIOTOXICITY; CHAGAS DISEASE; CLINICAL TRIAL; COMA; DIABETES MELLITUS; DIARRHEA; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; FEVER; GASTROINTESTINAL SYMPTOM; GENE SEQUENCE; GENOME; HEADACHE; HEART INJURY; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMUNOTHERAPY; INFLUENZA; INSOMNIA; KIDNEY FAILURE; KINETOPLASTIDA; LEUKOPENIA; LIPOGENESIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; RASH; SEIZURE; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOPHLEBITIS; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT; VACCINATION; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT REDUCTION;

CHAGAS DISEASE; CYSTEINE PROTEASES; ERGOSTEROL; HUMANS; LEISHMANIASIS, VISCERAL; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 77953504479     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790979953     Document Type: Article

References (271)

1. Manderson, L.; Aagaard-Hansen, J.; Allotey, P.; Gyapong, M.; Sommerfeld, J. Social research on neglected diseases of poverty: continuing and emerging themes. PLoS Negl. Trop. Dis., 2009, 3, e332.
2. WHO Neglected tropical diseases. Hidden successes, emerging opportunities. WHO/CDS/NTD/2006.2Geneva:WHO, 2006.
3. Yamey, G.; Torreele, E. The world's most neglected diseases. BMJ, 2002, 325, 176-7.
4. Peres, L.C.; Saggioro, F.P.; Dias, L.B., Jr.; Alves, V.A.; Brasil, R.A.; Luiz, V.E.; Neder, L.; Rosman, F.C.; Fleury, R.N.; Ura, S.; Orsi, A.T.; Talhari, C.; Ferreira, L.C.; Ramos, S.G.; Rey, L.C.; Martinez-Espinosa, F.E.; Sim, F.; Filho, O.E.; Duarte, M.I.; Lambertucci, J.R.; Chimelli, L.M.; Rosa, P.S.; Belone Ade, F. Infectious diseases in paediatric pathology: experience from a developing country. Pathology (Phila). 2008, 40, 161-75.
5. Croft, S.L.; Barrett, M.P.; Urbina, J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol, 2005, 21, 508-12.
6. Guerin, P.J.; Olliaro, P.; Sundar, S.; Boelaert, M.; Croft, S.L.; Desjeux, P.; Wasunna, M.K.; Bryceson, A.D. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis., 2002, 2, 494-501.
7. Kennedy, P.G. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann. Neurol., 2008, 64, 116-26.
8. Hunt, P. Economic, social and cultural rights, Report of the Special Rapporteur to the Commission on Human Rights. E/CN.4/2003/58. Geneva: Commission on Human Rights, 2003.
9. Legros, D.; Ollivier, G.; Gastellu-Etchegorry, M.; Paquet, C.; Burri, C.; Jannin, J.; Buscher, P. Treatment of human African trypanosomiasis--present situation and needs for research and development. Lancet Infect. Dis., 2002, 2, 437-40.
10. Berriman, M.; Ghedin, E.; Hertz-Fowler, C.; Blandin, G.; Renauld, H.; Bartholomeu, D.C.; Lennard, N.J.; Caler, E.; Hamlin, N.E.; Haas, B.; Bohme, U.; Hannick, L.; Aslett, M.A.; Shallom, J.; Marcello, L.; Hou, L.; Wickstead, B.; Alsmark, U.C.; Arrowsmith, C.; Atkin, R.J.; Barron, A.J.; Bringaud, F.; Brooks, K.; Carrington, M.; Cherevach, I.; Chillingworth, T.J.; Churcher, C.; Clark, L.N.; Corton, C.H.; Cronin, A.; Davies, R.M.; Doggett, J.; Djikeng, A.; Feldblyum, T.; Field, M.C.; Fraser, A.; Goodhead, I.; Hance, Z.; Harper, D.; Harris, B.R.; Hauser, H.; Hostetler, J.; Ivens, A.; Jagels, K.; Johnson, D.; Johnson, J.; Jones, K.; Kerhornou, A.X.; Koo, H.; Larke, N.; Landfear, S.; Larkin, C.; Leech, V.; Line, A.; Lord, A.; Macleod, A.; Mooney, P.J.; Moule, S.; Martin, D.M.; Morgan, G.W.; Mungall, K.; Norbertczak, H.; Ormond, D.; Pai, G.; Peacock, C.S.; Peterson, J.; Quail, M.A.; Rabbinowitsch, E.; Rajandream, M.A.; Reitter, C.; Salzberg, S.L.; Sanders, M.; Schobel, S.; Sharp, S.; Simmonds, M.; Simpson, A.J.; Tallon, L.; Turner, C.M.; Tait, A.; Tivey, A.R.; Van Aken, S.; Walker, D.; Wanless, D.; Wang, S.; White, B.; White, O.; Whitehead, S.; Woodward, J.; Wortman, J.; Adams, M.D.; Embley, T.M.; Gull, K.; Ullu, E.; Barry, J.D.; Fairlamb, A.H.; Opperdoes, F.; Barrell, B.G.; Donelson, J.E.; Hall, N.; Fraser, C.M.; Melville, S.E.; El-Sayed, N.M. The genome of the African trypanosome Trypanosoma brucei. Science, 2005, 309, 416-22.
11. El-Sayed, N.M.; Myler, P.J.; Bartholomeu, D.C.; Nilsson, D.; Aggarwal, G.; Tran, A.N.; Ghedin, E.; Worthey, E.A.; Delcher, A.L.; Blandin, G.; Westenberger, S.J.; Caler, E.; Cerqueira, G.C.; Branche, C.; Haas, B.; Anupama, A.; Arner, E.; Aslund, L.; Attipoe, P.; Bontempi, E.; Bringaud, F.; Burton, P.; Cadag, E.; Campbell, D.A.; Carrington, M.; Crabtree, J.; Darban, H.; da Silveira, J.F.; de Jong, P.; Edwards, K.; Englund, P.T.; Fazelina, G.; Feldblyum, T.; Ferella, M.; Frasch, A.C.; Gull, K.; Horn, D.; Hou, L.; Huang, Y.; Kindlund, E.; Klingbeil, M.; Kluge, S.; Koo, H.; Lacerda, D.; Levin, M.J.; Lorenzi, H.; Louie, T.; Machado, C.R.; McCulloch, R.; McKenna, A.; Mizuno, Y.; Mottram, J.C.; Nelson, S.; Ochaya, S.; Osoegawa, K.; Pai, G.; Parsons, M.; Pentony, M.; Pettersson, U.; Pop, M.; Ramirez, J.L.; Rinta, J.; Robertson, L.; Salzberg, S.L.; Sanchez, D.O.; Seyler, A.; Sharma, R.; Shetty, J.; Simpson, A.J.; Sisk, E.; Tammi, M.T.; Tarleton, R.; Teixeira, S.; Van Aken, S.; Vogt, C.; Ward, P.N.; Wickstead, B.; Wortman, J.; White, O.; Fraser, C.M.; Stuart, K.D.; Andersson, B. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science, 2005, 309, 409-15.
12. Peacock, C.S.; Seeger, K.; Harris, D.; Murphy, L.; Ruiz, J.C.; Quail, M.A.; Peters, N.; Adlem, E.; Tivey, A.; Aslett, M.; Kerhornou, A.; Ivens, A.; Fraser, A.; Rajandream, M.A.; Carver, T.; Norbertczak, H.; Chillingworth, T.; Hance, Z.; Jagels, K.; Moule, S.; Ormond, D.; Rutter, S.; Squares, R.; Whitehead, S.; Rabbinowitsch, E.; Arrowsmith, C.; White, B.; Thurston, S.; Bringaud, F.; Baldauf, S.L.; Faulconbridge, A.; Jeffares, D.; Depledge, D.P.; Oyola, S.O.; Hilley, J.D.; Brito, L.O.; Tosi, L.R.; Barrell, B.; Cruz, A.K.; Mottram, J.C.; Smith, D.F.; Berriman, M. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet., 2007, 39, 839-47.
13. Alvar, J.; Aparicio, P.; Aseffa, A.; Den Boer, M.; Canavate, C.; Dedet, J.P.; Gradoni, L.; Ter Horst, R.; Lopez-Velez, R.; Moreno, J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev., 2008, 21, 334-59, table of contents.
14. David, C.V.; Craft, N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther, 2009, 22, 491-502.
15. Alvar, J.; Croft, S.; Olliaro, P. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol., 2006, 61, 223-74.
16. Blackwell, J.M.; Fakiola, M.; Ibrahim, M.E.; Jamieson, S.E.; Jeronimo, S.B.; Miller, E.N.; Mishra, A.; Mohamed, H.S.; Peacock, C.S.; Raju, M.; Sundar, S.; Wilson, M.E. Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol., 2009, 31, 254-66.
17. Moraes, C.S.; Seabra, S.H.; Castro, D.P.; Brazil, R.P.; de Souza, W.; Garcia, E.S.; Azambuja, P. Leishmania (Leishmania) chagasi interactions with Serratia marcescens: ultrastructural studies, lysis and carbohydrate effects. Exp. Parasitol., 2008, 118, 561-8.
18. Desjeux, P. Leishmaniasis. Public health aspects and control. Clin. Dermatol., 1996, 14, 417-23.
19. Arias, J.R.; Monteiro, P.S.; Zicker, F. The reemergence of visceral leishmaniasis in Brazil. Emerg. Infect. Dis., 1996, 2, 145-6.
20. Boehme, C.C.; Hain, U.; Novosel, A.; Eichenlaub, S.; Fleischmann, E.; Loscher, T. Congenital visceral leishmaniasis. Emerg. Infect. Dis., 2006, 12, 359-60.
21. Bogdan, C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol, 2008, 10, 1221-34.
22. Alexander J, R.D. The interaction of leishmania species with macrophages. Adv. Parasitol., 1992, 31, 175-254.
23. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R.W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol., 2007, 5, 873-82.
24. Rittig, M.G.; Bogdan, C. Leishmania-host-cell interaction: complexities and alternative views. Parasitol. Today, 2000, 16, 292-7.
25. Sacks, D.L. Metacyclogenesis in Leishmania promastigotes. Exp. Parasitol., 1989, 69, 100-3.
26. Santos, D.O.; Coutinho, C.E.; Madeira, M.F.; Bottino, C.G.; Vieira, R.T.; Nascimento, S.B.; Bernardino, A.; Bourguignon, S.C.; Corte-Real, S.; Pinho, R.T.; Rodrigues, C.R.; Castro, H.C. Leishmaniasis treatment--a challenge that remains: a review. Parasitol. Res., 2008, 103, 1-10.
27. Shaw, J. The leishmaniases--survival and expansion in a changing world. A mini-review. Mem. Inst. Oswaldo Cruz, 2007, 102, 541-7.
28. Tripathi, P.; Singh, V.; Naik, S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol. Med. Microbiol., 2007, 51, 229-42.
29. Amato, V.S.; Tuon, F.F.; Bacha, H.A.; Neto, V.A.; Nicodemo, A.C. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop., 2008, 105, 1-9.
30. Agarwal, P.K. Miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med., 2003, 348, 857-8; author reply 57-8.
31. El-Masum, M.A.; Evans, D.A.; Minter, D.M.; El Harith, A. Visceral leishmaniasis in Bangladesh: the value of DAT as a diagnostic tool. Trans. R Soc. Trop. Med. Hyg., 1995, 89, 185-6.
32. El Harith, A.; Chowdhury, S.; Al-Masum, A.; Semiao-Santos, S.; Das, P.K.; Akhter, S.; Vetter, J.C.; Haq, I. Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions. J. Med. Microbiol., 1996, 44, 141-6.
33. Sacks, D.; Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol., 2002, 2, 845-58.
34. Hashim, F.A.; Khalil, E.A.; Ismail, A.; el Hassan, A.M. Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B. Trans. R. Soc. Trop. Med. Hyg., 1995, 89, 440.
35. Costa, J.M.; Garcia, A.M.; Rebelo, J.M.; Guimaraes, K.M.; Guimaraes, R.M.; Nunes, P.M. [Fatal case during treatment of american tegumentary leishmaniasis with sodium stibogluconate bp 88 (shandong xinhua)]. Rev. Soc. Bras. Med. Trop., 2003, 36, 295-8.
36. Sundar, S.; Sinha, P.R.; Agrawal, N.K.; Srivastava, R.; Rainey, P.M.; Berman, J.D.; Murray, H.W.; Singh, V.P. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg., 1998, 59, 139-43.
37. Wyllie, S.; Cunningham, M.L.; Fairlamb, A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem., 2004, 279, 39925-32.
38. Goodwin L.G.P.J. A study of the excretion of organic antimonias using a polarographic procedure. Biochem. J., 1943, 37, 198-209.
39. Cunningham, M.L.; Fairlamb, A.H. Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur. J. Biochem., 1995, 230, 460-8.
40. Sereno, D.; Holzmuller, P.; Mangot, I.; Cuny, G.; Ouaissi, A.; Lemesre, J.L. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother., 2001, 45, 2064-9.
41. Sudhandiran, G.; Shaha, C. Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol. Chem., 2003, 278, 25120-32.
42. Ferreira Cdos, S.; Martins, P.S.; Demicheli, C.; Brochu, C.; Ouellette, M.; Frezard, F. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinylglycine, cysteine and glutathione. Biometals, 2003, 16, 441-6.
43. Frezard, F.; Demicheli, C.; Ferreira, C.S.; Costa, M.A. Glutathioneinduced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob. Agents Chemother., 2001, 45, 913-6.
44. Denton, H.; McGregor, J.C.; Coombs, G.H. Reduction of antileishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J., 2004, 381, 405-12.
45. Berman, J.D.; Waddell, D.; Hanson, B.D. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother., 1985, 27, 916-20.
46. Berman, J.D.; Gallalee, J.V.; Best, J.M. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol., 1987, 36, 197-201.
47. Balana-Fouce, R.; Reguera, R.M.; Cubria, J.C.; Ordonez, D. The pharmacology of leishmaniasis. Gen. Pharmacol., 1998, 30, 435-43.
48. Reguera RM, C.J., Ordonez D The pharmacology of leishmaniasis. Gen. Pharmacol., 1998, 30, 435-43.
49. WHO Expert committee report: Control of the leishmaniasis. Technical report series 793, 1991.
50. Helmick, C.G.; Green, J.K. Pentamidine-associated hypotension and route of administration. Ann. Intern. Med., 1985, 103, 480.
51. Wood, D.H.; Hall, J.E.; Rose, B.G.; Tidwell, R.R. 1,5-Bis(4amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. Eur. J. Pharmacol., 1998, 353, 97-103.
52. Dietze, R.; Fagundes, S.M.; Brito, E.F.; Milan, E.P.; Feitosa, T.F.; Suassuna, F.A.; Fonschiffrey, G.; Ksionski, G.; Dember, J. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Trop. Med. Hyg., 1995, 89, 309-11.
53. Thakur, C.P.; Bhowmick, S.; Dolfi, L.; Olliaro, P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans. R. Soc. Trop. Med. Hyg., 1995, 89, 219-23.
54. Basselin, M.; Lawrence, F.; Robert-Gero, M. Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem. J, 1996, 315 (Pt 2), 631-4.
55. Bray, P.G.; Barrett, M.P.; Ward, S.A.; de Koning, H.P. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol, 2003, 19, 232-9.
56. Sundar, S.; Chatterjee, M. Visceral leishmaniasis current therapeutic modalities. Indian J. Med. Res., 2006, 123, 345-52.
57. Balaña-Foucea, R.; O.D., Alunda, J.M. Putrescine transport system in Leishmania infanutm promastigotes. Mol. Biochem. Parasitol., 1989, 35, 43-50.
58. Karvonen, E.; Kauppinen, L.; Partanen, T.; Poso, H. Irreversible inhibition of putrescine-stimulated S-adenosyl-L-methionine decarboxylase by berenil and pentamidine. Biochem. J., 1985, 231, 165-9.
59. Johnson, R.; Cubria, J.C.; Reguera, R.M.; Balana-Fouce, R.; Ordonez, D. Interaction of cationic diamidines with Leishmania infantum DNA. Biol. Chem., 1998, 379, 925-30.
60. Calonge, M.; Johnson, R.; Balana-Fouce, R.; Ordonez, D. Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. Biochem. Pharmacol., 1996, 52, 835-41.
61. Verma, N.K.; Dey, C.S. Possible mechanism of miltefosinemediated death of Leishmania donovani. Antimicrob. Agents Chemother., 2004, 48, 3010-5.
62. Croft, S.L.; Engel, J. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg., 2006, 100 Suppl 1, S4-8.
63. Croft, S.L.; Seifert, K.; Duchene, M. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol., 2003, 126, 165-72.
64. Perez-Victoria, F.J.; Gamarro, F.; Ouellette, M.; Castanys, S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem., 2003, 278, 49965-71.
65. Sundar, S.; Olliaro, P.L. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag., 2007, 3, 733-40.
66. Perez-Victoria, F.J.; Castanys, S.; Gamarro, F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother., 2003, 47, 2397-403.
67. de Castroa, S.L.; Santa-Ritaa, R.M.; Urbinab, J.A.; Croftc, S.L. Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells. Mini Rev. Med. Chem., 2004, 4, 141-51.
68. Luque-Ortega, J.R.; Rivas, L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2007, 51, 1327-32.
69. Lux, H.; Hart, D.T.; Parker, P.J.; Klenner, T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol., 1996, 416, 201-11.
70. Palumbo, E. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review. Brazil. J. Infect. Dis., 2008, 12, 2-4.
71. Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Opperdoes, F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania. Mol. Biochem. Parasitol., 2000, 111, 1-14.
72. Serrano-Martin, X.; Payares, G.; De Lucca, M.; Martinez, J.C.; Mendoza-Leon, A.; Benaim, G. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob. Agents Chemother., 2009, 53, 5108-13.
73. Paris, C.; Loiseau, P.M.; Bories, C.; Breard, J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2004, 48, 852-9.
74. Wieder, T.; Orfanos, C.E.; Geilen, C.C. Induction of ceramidemediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem., 1998, 273, 11025-31.
75. Wright, M.M.; Howe, A.G.; Zaremberg, V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem. Cell Biol., 2004, 82, 18-26.
76. Gajate, C.; Mollinedo, F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab., 2002, 3, 491-525.
77. Rakotomanga, M.; Saint-Pierre-Chazalet, M.; Loiseau, P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drugmembrane interactions. Antimicrob. Agents Chemother., 2005, 49, 2677-86.
78. Olliaro, P.L.; Bryceson, A.D. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today, 1993, 9, 323-8.
79. Maarouf, M.; Lawrence, F.; Croft, S.L.; Robert-Gero, M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res., 1995, 81, 421-5.
80. Maarouf, M.; de Kouchkovsky, Y.; Brown, S.; Petit, P.X.; Robert-Gero, M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell Res., 1997, 232, 339-48.
81. Jhingran, A.; Chawla, B.; Saxena, S.; Barrett, M.P.; Madhubala, R. Paromomycin: uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 2009, 164, 111-7.
82. Vennerstrom, J.L.; Klayman, D.L. Protoberberine alkaloids as antimalarials. J. Med. Chem., 1988, 31, 1084-7.
83. Das, M.; Mukherjee, S.B.; Shaha, C. Hydrogen peroxide induces apoptosis-like death in Leishmania donovani promastigotes. J. Cell Sci., 2001, 114, 2461-9.
84. Ghosh, A.K.; Bhattacharyya, F.K.; Ghosh, D.K. Leishmania donovani: amastigote inhibition and mode of action of berberine. Exp. Parasitol., 1985, 60, 404-13.
85. Ghosh, A.K.; Rakshit, M.M.; Ghosh, D.K. Effect of berberine chloride on Leishmania donovani. Indian J. Med. Res., 1983, 78, 407-16.
86. Putzer, B. Berberine and its derivatives in the treatment of oriental sore. Med. Chem. Aspects, 1934, 2, 274-80.
87. Vennerstrom, J.L.; Lovelace, J.K.; Waits, V.B.; Hanson, W.L.; Klayman, D.L. Berberine derivatives as antileishmanial drugs. Antimicrob. Agents Chemother., 1990, 34, 918-21.
88. Squires, K.E.; Rosenkaimer, F.; Sherwood, J.A.; Forni, A.L.; Were, J.B.; Murray, H.W. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am. J. Trop. Med. Hyg., 1993, 48, 666-9.
89. Rosenthal, E.; Marty, P. Recent understanding in the treatment of visceral leishmaniasis. J. Postgrad. Med., 2003, 49, 61-8.
90. Badaro, R.; Falcoff, E.; Badaro, F.S.; Carvalho, E.M.; Pedral-Sampaio, D.; Barral, A.; Carvalho, J.S.; Barral-Netto, M.; Brandely, M.; Silva, L.; et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med., 1990, 322, 16-21.
91. Sundar, S.; Murray, H.W. Effect of treatment with interferongamma alone in visceral leishmaniasis. J. Infect. Dis., 1995, 172, 1627-9.
92. Sundar, S.; Rosenkaimer, F.; Murray, H.W. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis., 1994, 170, 659-62.
93. Sundar, S.; Singh, V.P.; Sharma, S.; Makharia, M.K.; Murray, H.W. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis., 1997, 176, 1117-9.
94. van Lunzen, J.; Kern, P.; Schmitz, J.; Brzoska, J.; Flessenkamper, S.; Dietrich, M. Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and pentavalent antimony. Infection, 1993, 21, 362-6.
95. Sundar, S.; Rosenkaimer, F.; Lesser, M.L.; Murray, H.W. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J. Infect. Dis., 1995, 171, 992-6.
96. Chagas, C. Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen, n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz, 1909, 1, 11-80.
97. WHO Control of Chagas disease. World Health Organ. Tech. Rep. Ser., 2002, 905, i-vi, 1-109, back cover.
98. PAHO/WHO Update of American Trypanosomiasis and Leishmaniasis Control and Research -Final Report. PAHO/HDM/CD/512, 2008.
99. Prata, A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis, 2001, 1, 92-100.
100. Carod-Artal, F.J. Stroke: a neglected complication of American trypanosomiasis (Chagas' disease). Trans. R. Soc. Trop. Med. Hyg., 2007, 101, 1075-80.
101. Rozendaal, J.A. Vector control: methods for use by individuals and communities. World Health Organization, 1997.
102. Moncayo, A.; Ortiz Yanine, M.I. An update on Chagas disease (human American trypanosomiasis). Ann. Trop. Med. Parasitol., 2006, 100, 663-77.
103. Duschak, V.G.; Couto, A.S. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Patents Anti-Infect. Drug Disc., 2007, 2, 19-51.
104. Bern, C.; Montgomery, S.P.; Herwaldt, B.L.; Rassi, A., Jr.; Marin-Neto, J.A.; Dantas, R.O.; Maguire, J.H.; Acquatella, H.; Morillo, C.; Kirchhoff, L.V.; Gilman, R.H.; Reyes, P.A.; Salvatella, R.; Moore, A.C. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA, 2007, 298, 2171-81.
105. Maya, J.D.; Cassels, B.K.; Iturriaga-Vasquez, P.; Ferreira, J.; Faundez, M.; Galanti, N.; Ferreira, A.; Morello, A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A. Mol. Integr. Physiol., 2007, 146, 601-20.
106. Bastien, J.W. The Kiss of Death. Chagas' Disease in the Americas. University of Utah Press: Salt Lake City, 1998.
107. Yacoub, S.; Mocumbi, A.O.; Yacoub, M.H. Neglected tropical cardiomyopathies: I. Chagas disease: myocardial disease. Heart, 2008, 94, 244-8.
108. Burleigh, B.A.; Andrews, N.W. The mechanisms of Trypanosoma cruzi invasion of mammalian cells. Annu. Rev. Microbiol., 1995, 49, 175-200.
109. Tyler, K.M.; Engman, D.M. The life cycle of Trypanosoma cruzi revisited. Int. J. Parasitol., 2001, 31, 472-81.
110. Andrade, Z.A. Immunopathology of Chagas disease. Mem. Inst. Oswaldo Cruz, 1999, 94 (Suppl 1), 71-80.
111. Dias, J.C. The indeterminate form of human chronic Chagas' disease A clinical epidemiological review. Rev. Soc. Bras. Med. Trop., 1989, 22, 147-56.
112. Sosa Estani, S.; Segura, E.L.; Ruiz, A.M.; Velazquez, E.; Porcel, B.M.; Yampotis, C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg., 1998, 59, 526-9.
113. de Andrade, A.L.; Zicker, F.; de Oliveira, R.M.; Almeida Silva, S.; Luquetti, A.; Travassos, L.R.; Almeida, I.C.; de Andrade, S.S.; de Andrade, J.G.; Martelli, C.M. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet, 1996, 348, 1407-13.
114. Perez-Molina, J.A.; Perez-Ayala, A.; Moreno, S.; Fernandez-Gonzalez, M.C.; Zamora, J.; Lopez-Velez, R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a metaanalysis. J. Antimicrob. Chemother., 2009, 64, 1139-47.
115. Kierszenbaum, F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol, 2005, 21, 513-6.
116. Hyland, K.V.; Engman, D.M. Further thoughts on where we stand on the autoimmunity hypothesis of Chagas disease. Trends Parasitol., 2006, 22, 101-2; author reply 03.
117. Dutra, W.O.; Gollob, K.J. Current concepts in immunoregulation and pathology of human Chagas disease. Curr. Opin. Infect. Dis., 2008, 21, 287-92.
118. Ferrari, I.; Levin, M.J.; Wallukat, G.; Elies, R.; Lebesgue, D.; Chiale, P.; Elizari, M.; Rosenbaum, M.; Hoebeke, J. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1adrenergic receptor. J. Exp. Med., 1995, 182, 59-65.
119. Cunha-Neto, E.; Bilate, A.M.; Hyland, K.V.; Fonseca, S.G.; Kalil, J.; Engman, D.M. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity, 2006, 39, 41-54.
120. Leon, J.S.; Godsel, L.M.; Wang, K.; Engman, D.M. Cardiac myosin autoimmunity in acute Chagas' heart disease. Infect. Immun., 2001, 69, 5643-9.
121. Girones, N.; Cuervo, H.; Fresno, M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr. Top. Microbiol. Immunol., 2005, 296, 89-123.
122. Harms, G.; Feldmeier, H. The impact of HIV infection on tropical diseases. Infect. Dis. Clin. North Am., 2005, 19, 121-35, ix.
123. Rodriques Coura, J.; de Castro, S.L. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz, 2002, 97, 3-24.
124. Da-Cruz, A.M.; Igreja, R.P.; Dantas, W.; Junqueira, A.C.; Pacheco, R.S.; Silva-Goncalves, A.J.; Pirmez, C. Long-term follow-up of coinfected HIV and Trypanosoma cruzi Brazilian patients. Trans. R. Soc. Trop. Med. Hyg., 2004, 98, 728-33.
125. Karp, C.L.; Auwaerter, P.G. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clin. Infect. Dis., 2007, 45, 1214-20.
126. Camargo, M.E. Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev. Inst. Med. Trop. Sao Paulo, 1966, 8, 227-35.
127. Cerisola, J.A.; Fatala Chaben, M.; Lazzari, J.O. [Hemagglutination test for the diagnosis of Chagas' disease.]. Prensa Med. Argent., 1962, 49, 1761-7.
128. Voller, A.; Draper, C.; Bidwell, D.E.; Bartlett, A. Microplate enzyme-linked immunosorbent assay for chagas' disease. Lancet, 1975, 1, 426-8.
129. Gomes, Y.M.; Lorena, V.M.; Luquetti, A.O. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem. Inst. Oswaldo Cruz, 2009, 104 Suppl 1, 115-21.
130. International meeting: new diagnostic tests are urgently needed to treat patients with Chagas disease. Rev. Soc. Bras. Med. Trop., 2008, 41, 315-9.
131. Tekiel, V.; Alba-Soto, C.D.; Gonzalez Cappa, S.M.; Postan, M.; Sanchez, D.O. Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine, 2009, 27, 1323-32.
132. Silveira, E.L.; Claser, C.; Haolla, F.A.; Zanella, L.G.; Rodrigues, M.M. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease. Clin. Vaccine Immunol., 2008, 15, 1292-300.
133. Bhatia, V.; Garg, N.J. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin. Vaccine Immunol., 2008, 15, 1158-64.
134. Castro, J.A.; de Mecca, M.M.; Bartel, L.C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol., 2006, 25, 471-9.
135. Docampo, R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact., 1990, 73, 1-27.
136. Viode, C.; Bettache, N.; Cenas, N.; Krauth-Siegel, R.L.; Chauviere, G.; Bakalara, N.; Perie, J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol., 1999, 57, 549-57.
137. Henderson, G.B.; Ulrich, P.; Fairlamb, A.H.; Rosenberg, I.; Pereira, M.; Sela, M.; Cerami, A. Subversive substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 5374-8.
138. Blumenstiel, K.; Schoneck, R.; Yardley, V.; Croft, S.L.; Krauth-Siegel, R.L. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem. Pharmacol., 1999, 58, 1791-9.
139. Castro, J.A. Contributions of toxicology to the problem of Chagas' disease (American Trypanosomiasis)--a year 2000 update. Biomed. Environ. Sci., 2000, 13, 271-9.
140. Moreno, S.N.; Docampo, R.; Mason, R.P.; Leon, W.; Stoppani, A.O. Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations. Arch. Biochem. Biophys., 1982, 218, 585-91.
141. Temperton, N.J.; Wilkinson, S.R.; Meyer, D.J.; Kelly, J.M. Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocidal agents gentian violet and benznidazole. Mol. Biochem. Parasitol., 1998, 96, 167-76.
142. Docampo, R.; Stoppani, A.O. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys., 1979, 197, 317-21.
143. Diaz de Toranzo, E.G.; Castro, J.A.; Franke de Cazzulo, B.M.; Cazzulo, J.J. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia, 1988, 44, 880-1.
144. Fulton, J.D.; Spooner, D.F. Inhibition of the respiration of Trypanosoma rhodesiense by thiols. Biochem. J., 1956, 63, 475-81.
145. Docampo, R.; Cruz, F.S.; Boveris, A.; Muniz, R.P.; Esquivel, D.M. Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in beta-lapachone-treated Trypanosoma cruzi epimastigotes. Arch. Biochem. Biophys., 1978, 186, 292-7.
146. Kubata, B.K.; Kabututu, Z.; Nozaki, T.; Munday, C.J.; Fukuzumi, S.; Ohkubo, K.; Lazarus, M.; Maruyama, T.; Martin, S.K.; Duszenko, M.; Urade, Y. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med., 2002, 196, 1241-51.
147. Wilkinson, S.R.; Taylor, M.C.; Horn, D.; Kelly, J.M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 5022-7.
148. Roldan, M.D.; Perez-Reinado, E.; Castillo, F.; Moreno-Vivian, C. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol. Rev., 2008, 32, 474-500.
149. Peterson, F.J.; Mason, R.P.; Hovsepian, J.; Holtzman, J.L. Oxygensensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem., 1979, 254, 4009-14.
150. Prathalingham, S.R.; Wilkinson, S.R.; Horn, D.; Kelly, J.M. Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrob. Agents Chemother., 2007, 51, 755-8.
151. Rassi, A., Jr.; Dias, J.C.; Marin-Neto, J.A.; Rassi, A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart, 2009, 95, 524-34.
152. Jannin, J.; Villa, L. An overview of Chagas disease treatment. Mem. Inst. Oswaldo Cruz, 2007, 102 Suppl 1, 95-7.
153. Drugs For Parasitic Infections. The Medical Letter: New Rochelle (NY), 2004.
154. Bartel, L.C.; Montalto de Mecca, M.; Fanelli, S.L.; Rodriguez de Castro, C.; Diaz, E.G.; Castro, J.A. Early nifurtimox-induced biochemical and ultrastructural alterations in rat heart. Hum. Exp. Toxicol., 2007, 26, 781-8.
155. Mecca, M.M.; Bartel, L.C.; Castro, C.R.; Castro, J.A. Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects. Mem. Inst. Oswaldo Cruz, 2008, 103, 549-53.
156. Nagel, R. Genotoxicity studies with two antichagasic drugs. Mutat. Res., 1987, 191, 17-20.
157. Nagel, R.; Nepomnaschy, I. Mutagenicity of 2 anti-chagasic drugs and their metabolic deactivation. Mutat. Res., 1983, 117, 237-42.
158. Gorla, N.B.; Castro, J.A. Micronucleus formation in bone marrow of mice treated with nifurtimox or benznidazole. Toxicol. Lett., 1985, 25, 259-63.
159. Masana, M.; de Toranzo, E.G.; Castro, J.A. Reductive metabolism and activation of benznidazole. Biochem. Pharmacol., 1984, 33, 1041-5.
160. Murta, S.M.; Ropert, C.; Alves, R.O.; Gazzinelli, R.T.; Romanha, A.J. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drugresistant Trypansoma cruzi population. Parasite Immunol., 1999, 21, 535-44.
161. Romanha, A.J.; Alves, R.O.; Murta, S.M.; Silva, J.S.; Ropert, C.; Gazzinelli, R.T. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J. Infect. Dis., 2002, 186, 823-8.
162. Soares Sobrinho, J.L.; Na, A.L.L.; Perrelli, D.C.; da Silva, J.L.; Morais de Medeiros, F.L.; de La Roca Soares, M.F.; Rolim Neto, P.J. Development and in vitro evaluation of tablets based on the antichagasic benznidazole. Brazil. J. Pharm. Sci., 2008, 44, 383-89.
163. Teixeira, A.R.; Cordoba, J.C.; Souto Maior, I.; Solorzano, E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am. J. Trop. Med. Hyg., 1990, 43, 146-58.
164. Voogd, C.E.; van der Stel, J.J.; Jacobs, J.J. The mutagenic action of nitroimidazoles. IV. A comparison of the mutagenic action of several nitroimidazoles and some imidazoles. Mutat. Res., 1979, 66, 207-21.
165. Urbina, J.A.; Docampo, R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol., 2003, 19, 495-501.
166. Cerecetto, H.; Gonzalez, M. Chemotherapy of Chagas' disease: status and new developments. Curr. Top. Med. Chem., 2002, 2, 1187-213.
167. Doyle, P.S.; Sajid, M.; O'Brien, T.; Dubois, K.; Engel, J.C.; Mackey, Z.B.; Reed, S. Drugs targeting parasite lysosomes. Curr. Pharm. Des., 2008, 14, 889-900.
168. Cazzulo, J.J. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. Curr. Top. Med. Chem., 2002, 2, 1261-71.
169. Itow, S.; Camargo, E.P. Proteolytic activites in cell extracts of Trypanosoma cruzi. J. Protozool., 1977, 24, 591-5.
170. Bontempi, E.; Martinez, J.; Cazzulo, J.J. Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol. Biochem. Parasitol., 1989, 33, 43-7.
171. Soares, M.J.; Souto-Padron, T.; De Souza, W. Identification of a large pre-lysosomal compartment in the pathogenic protozoon Trypanosoma cruzi. J. Cell Sci., 1992, 102 (Pt 1), 157-67.
172. Souto-Padron, T.; Campetella, O.E.; Cazzulo, J.J.; de Souza, W. Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction. J. Cell Sci., 1990, 96 (Pt 3), 485-90.
173. Harth, G.; Andrews, N.; Mills, A.A.; Engel, J.C.; Smith, R.; McKerrow, J.H. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol. Biochem. Parasitol., 1993, 58, 17-24.
174. Engel, J.C.; Doyle, P.S.; Palmer, J.; Hsieh, I.; Bainton, D.F.; McKerrow, J.H. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci., 1998, 111 (Pt 5), 597-606.
175. Engel, J.C.; Doyle, P.S.; Hsieh, I.; McKerrow, J.H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med., 1998, 188, 725-34.
176. Doyle, P.S.; Zhou, Y.M.; Engel, J.C.; McKerrow, J.H. A cysteine protease inhibitor cures Chagas' disease in an immunodeficientmouse model of infection. Antimicrob. Agents Chemother., 2007, 51, 3932-9.
177. Lalmanach, G.; Mayer, R.; Serveau, C.; Scharfstein, J.; Gauthier, F. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem. J., 1996, 318(Pt 2), 395-9.
178. Hernandez, A.A.; Roush, W.R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol., 2002, 6, 459-65.
179. Li, R.; Chen, X.; Gong, B.; Selzer, P.M.; Li, Z.; Davidson, E.; Kurzban, G.; Miller, R.E.; Nuzum, E.O.; McKerrow, J.H.; Fletterick, R.J.; Gillmor, S.A.; Craik, C.S.; Kuntz, I.D.; Cohen, F.E.; Kenyon, G.L. Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem., 1996, 4, 1421-7.
180. Du, X.; Hansell, E.; Engel, J.C.; Caffrey, C.R.; Cohen, F.E.; McKerrow, J.H. Aryl ureas represent a new class of antitrypanosomal agents. Chem. Biol., 2000, 7, 733-42.
181. Gotz, M.G.; Caffrey, C.R.; Hansell, E.; McKerrow, J.H.; Powers, J.C. Peptidyl allyl sulfones: a new class of inhibitors for clan CA cysteine proteases. Bioorg. Med. Chem., 2004, 12, 5203-11.
182. Fujii, N.; Mallari, J.P.; Hansell, E.J.; Mackey, Z.; Doyle, P.; Zhou, Y.M.; Gut, J.; Rosenthal, P.J.; McKerrow, J.H.; Guy, R.K. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg. Med. Chem. Lett., 2005, 15, 121-3.
183. Neres, J.; Bryce, R.A.; Douglas, K.T. Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease. Drug Discov. Today, 2008, 13, 110-7.
184. Taylor, G. Sialidases: structures, biological significance and therapeutic potential. Curr. Opin. Struct. Biol., 1996, 6, 830-7.
185. Buscaglia, C.A.; Campo, V.A.; Frasch, A.C.; Di Noia, J.M. Trypanosoma cruzi surface mucins: host-dependent coat diversity. Nat. Rev. Microbiol., 2006, 4, 229-36.
186. Cremona, M.L.; Campetella, O.; Sanchez, D.O.; Frasch, A.C. Enzymically inactive members of the trans-sialidase family from Trypanosoma cruzi display beta-galactose binding activity. Glycobiology, 1999, 9, 581-7.
187. Schenkman, S.; Jiang, M.S.; Hart, G.W.; Nussenzweig, V. A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stagespecific epitope required for invasion of mammalian cells. Cell, 1991, 65, 1117-25.
188. Tomlinson, S.; Raper, J. Natural human immunity to trypanosomes. Parasitol Today, 1998, 14, 354-9.
189. Todeschini, A.R.; Girard, M.F.; Wieruszeski, J.M.; Nunes, M.P.; DosReis, G.A.; Mendonca-Previato, L.; Previato, J.O. trans-Sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner. J. Biol. Chem., 2002, 277, 45962-8.
190. Ming, M.; Chuenkova, M.; Ortega-Barria, E.; Pereira, M.E. Mediation of Trypanosoma cruzi invasion by sialic acid on the host cell and trans-sialidase on the trypanosome. Mol. Biochem. Parasitol., 1993, 59, 243-52.
191. Kim, C.U.; Lew, W.; Williams, M.A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Mendel, D.B.; Tai, C.Y.; Laver, W.G.; Stevens, R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc., 1997, 119, 681-90.
192. Chand, P.; Babu, Y.S.; Bantia, S.; Chu, N.; Cole, L.B.; Kotian, P.L.; Laver, W.G.; Montgomery, J.A.; Pathak, V.P.; Petty, S.L.; Shrout, D.P.; Walsh, D.A.; Walsh, G.M. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J. Med. Chem., 1997, 40, 4030-52.
193. von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Van Phan, T.; Smythe, M.L.; White, H.F.; Oliver, S.W.; Colman, P.M.; Varghese, J.N.; Ryan, D.M.; Woods, J.M.; Bethell, R.V.; Hotham, V.J.; Cameron, J.M.; Penn, C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-23.
194. Paris, G.; Ratier, L.; Amaya, M.F.; Nguyen, T.; Alzari, P.M.; Frasch, A.C. A sialidase mutant displaying trans-sialidase activity. J. Mol. Biol., 2005, 345, 923-34.
195. Watts, A.G.; Damager, I.; Amaya, M.L.; Buschiazzo, A.; Alzari, P.; Frasch, A.C.; Withers, S.G. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J. Am. Chem. Soc., 2003, 125, 7532-3.
196. Neres, J.; Bonnet, P.; Edwards, P.N.; Kotian, P.L.; Buschiazzo, A.; Alzari, P.M.; Bryce, R.A.; Douglas, K.T. Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase. Bioorg. Med. Chem., 2007, 15, 2106-19.
197. Chand, P.; Kotian, P.L.; Morris, P.E.; Bantia, S.; Walsh, D.A.; Babu, Y.S. Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. Bioorg. Med. Chem., 2005, 13, 2665-78.
198. Vandekerckhove, F.; Schenkman, S.; Pontes de Carvalho, L.; Tomlinson, S.; Kiso, M.; Yoshida, M.; Hasegawa, A.; Nussenzweig, V. Substrate specificity of the Trypanosoma cruzi trans-sialidase. Glycobiology, 1992, 2, 541-8.
199. Busse, H.; Hakoda, M.; Stanley, M.; Streicher, H. Galactose-Phosphonates as Mimetics of the Sialyltransfer by Trypanosomal [Sialidases. J. Carbohydr. Chem., 2007, 26, 159-94.
200. Agusti, R.; Paris, G.; Ratier, L.; Frasch, A.C.; de Lederkremer, R.M. Lactose derivatives are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional substrates in vitro and in vivo. Glycobiology, 2004, 14, 659-70.
201. Neres, J.; Brewer, M.L.; Ratier, L.; Botti, H.; Buschiazzo, A.; Edwards, P.N.; Mortenson, P.N.; Charlton, M.H.; Alzari, P.M.; Frasch, A.C.; Bryce, R.A.; Douglas, K.T. Discovery of novel inhibitors of Trypanosoma cruzitrans-sialidase from in silico screening. Bioorg. Med. Chem. Lett., 2009, 19, 589-96.
202. Roberts, C.W.; McLeod, R.; Rice, D.W.; Ginger, M.; Chance, M.L.; Goad, L.J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol., 2003, 126, 129-42.
203. Braga, M.V.; Urbina, J.A.; de Souza, W. Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents, 2004, 24, 72-8.
204. Garzoni, L.R.; Caldera, A.; Meirelles Mde, N.; de Castro, S.L.; Docampo, R.; Meints, G.A.; Oldfield, E.; Urbina, J.A. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Agents, 2004, 23, 273-85.
205. Urbina, J.A. Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med., 1999, 77, 332-8.
206. Lepesheva, G.I.; Waterman, M.R. CYP51--the omnipotent P450. Mol. Cell. Endocrinol., 2004, 215, 165-70.
207. Urbina, J.A.; Payares, G.; Molina, J.; Sanoja, C.; Liendo, A.; Lazardi, K.; Piras, M.M.; Piras, R.; Perez, N.; Wincker, P.; Ryley, J.F. Cure of shortand long-term experimental Chagas' disease using D0870. Science, 1996, 273, 969-71.
208. Molina, J.; Martins-Filho, O.; Brener, Z.; Romanha, A.J.; Loebenberg, D.; Urbina, J.A. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother., 2000, 44, 150-5.
209. Urbina, J.A.; Payares, G.; Sanoja, C.; Molina, J.; Lira, R.; Brener, Z.; Romanha, A.J. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents, 2003, 21, 39-48.
210. Corrales, M.; Cardozo, R.; Segura, M.A.; Urbina, J.A.; Basombrio, M.A. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother., 2005, 49, 1556-60.
211. Urbina, J.A.; Payares, G.; Sanoja, C.; Lira, R.; Romanha, A.J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents, 2003, 21, 27-38.
212. Urbina, J.A.; Lira, R.; Visbal, G.; Bartroli, J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 2000, 44, 2498-502.
213. Guedes, P.M.; Urbina, J.A.; de Lana, M.; Afonso, L.C.; Veloso, V.M.; Tafuri, W.L.; Machado-Coelho, G.L.; Chiari, E.; Bahia, M.T. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother., 2004, 48, 4286-92.
214. Benaim, G.; Sanders, J.M.; Garcia-Marchan, Y.; Colina, C.; Lira, R.; Caldera, A.R.; Payares, G.; Sanoja, C.; Burgos, J.M.; Leon-Rossell, A.; Concepcion, J.L.; Schijman, A.G.; Levin, M.; Oldfield, E.; Urbina, J.A. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem., 2006, 49, 892-9.
215. Joubert, B.M.; Buckner, F.S.; Matsuda, S.P. Trypanosome and animal lanosterol synthases use different catalytic motifs. Org. Lett., 2001, 3, 1957-60.
216. Buckner, F.S.; Griffin, J.H.; Wilson, A.J.; Van Voorhis, W.C. Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother., 2001, 45, 1210-5.
217. Balliano, G.; Dehmlow, H.; Oliaro-Bosso, S.; Scaldaferri, M.; Taramino, S.; Viola, F.; Caron, G.; Aebi, J.; Ackermann, J. Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: a model for the development of novel antiparasitic agents. Bioorg. Med. Chem. Lett., 2009, 19, 718-23.
218. Elhalem, E.; Bailey, B.N.; Docampo, R.; Ujvary, I.; Szajnman, S.H.; Rodriguez, J.B. Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi. J. Med. Chem., 2002, 45, 3984-99.
219. Szajnman, S.H.; Yan, W.; Bailey, B.N.; Docampo, R.; Elhalem, E.; Rodriguez, J.B. Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J. Med. Chem., 2000, 43, 1826-40.
220. Urbina, J.A.; Concepcion, J.L.; Caldera, A.; Payares, G.; Sanoja, C.; Otomo, T.; Hiyoshi, H. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother., 2004, 48, 2379-87.
221. Kennedy, P.G. Human African trypanosomiasis of the CNS: current issues and challenges. J. Clin. Invest., 2004, 113, 496-504.
222. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly. Epidemiol. Rec., 2006, 81, 71-80.
223. Donelson, J.E. Antigenic variation and the African trypanosome genome. Acta Trop., 2003, 85, 391-404.
224. Smith, D.H.; Pepin, J.; Stich, A.H. Human African trypanosomiasis: an emerging public health crisis. Br. Med. Bull., 1998, 54, 341-55.
225. Fenn, K.; Matthews, K.R. The cell biology of Trypanosoma brucei differentiation. Curr. Opin. Microbiol., 2007, 10, 539-46.
226. Truc, P.; Lejon, V.; Magnus, E.; Jamonneau, V.; Nangouma, A.; Verloo, D.; Penchenier, L.; Buscher, P. Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. Bull. World Health Organ., 2002, 80, 882-6.
227. Jamonneau, V.; Solano, P.; Garcia, A.; Lejon, V.; Dje, N.; Miezan, T.W.; N'Guessan, P.; Cuny, G.; Buscher, P. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Cote d'Ivoire. Trop. Med. Int. Health, 2003, 8, 589-94.
228. Njiru, Z.K.; Mikosza, A.S.; Armstrong, T.; Enyaru, J.C.; Ndung'u, J.M.; Thompson, A.R. Loop-Mediated Isothermal Amplification (LAMP) Method for Rapid Detection of Trypanosoma brucei rhodesiense. PLoS Negl. Trop. Dis., 2008, 2, e147.
229. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser., 1998, 881, I-VI, 1-114.
230. Cross, G.A. Antigenic variation in trypanosomes: secrets surface slowly. Bioessays, 1996, 18, 283-91.
231. Vansterkenburg, E.L.; Coppens, I.; Wilting, J.; Bos, O.J.; Fischer, M.J.; Janssen, L.H.; Opperdoes, F.R. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop., 1993, 54, 237-50.
232. Collins, J.M.; Klecker, R.W., Jr.; Yarchoan, R.; Lane, H.C.; Fauci, A.S.; Redfield, R.R.; Broder, S.; Myers, C.E. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol., 1986, 26, 22-6.
233. Pal, A.; Hall, B.S.; Field, M.C. Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. Mol. Biochem. Parasitol., 2002, 122, 217-21.
234. Nok, A.J. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol. Res., 2003, 90, 71-9.
235. Bouteille, B.; Oukem, O.; Bisser, S.; Dumas, M. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol., 2003, 17, 171-81.
236. Delespaux, V.; de Koning, H.P. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat, 2007, 10, 30-50.
237. Carter, N.S.; Fairlamb, A.H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature, 1993, 361, 173-6.
238. de Koning, H.P. Transporters in African trypanosomes: role in drug action and resistance. Int. J. Parasitol., 2001, 31, 512-22.
239. Berger, B.J.; Carter, N.S.; Fairlamb, A.H. Polyamine and pentamidine metabolism in African trypanosomes. Acta Trop., 1993, 54, 215-24.
240. Matovu, E.; Stewart, M.L.; Geiser, F.; Brun, R.; Maser, P.; Wallace, L.J.; Burchmore, R.J.; Enyaru, J.C.; Barrett, M.P.; Kaminsky, R.; Seebeck, T.; de Koning, H.P. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot. Cell, 2003, 2, 1003-8.
241. Docampo, R.; Moreno, S.N. Current chemotherapy of human African trypanosomiasis. Parasitol. Res., 2003, 90 Supp 1, S10-3.
242. Fairlamb, A.H.; Henderson, G.B.; Cerami, A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 2607-11.
243. Pepin, J.; Milord, F. The treatment of human African trypanosomiasis. Adv. Parasitol., 1994, 33, 1-47.
244. Burri, C.; Nkunku, S.; Merolle, A.; Smith, T.; Blum, J.; Brun, R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet, 2000, 355, 1419-25.
245. Kuzoe, F.A. Current situation of African trypanosomiasis. Acta Trop., 1993, 54, 153-62.
246. Legros, D.; Evans, S.; Maiso, F.; Enyaru, J.C.; Mbulamberi, D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans. R. Soc. Trop. Med. Hyg., 1999, 93, 439-42.
247. Iten, M.; Mett, H.; Evans, A.; Enyaru, J.C.; Brun, R.; Kaminsky, R. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alphadifluoromethylornithine. Antimicrob. Agents Chemother., 1997, 41, 1922-5.
248. Balasegaram, M.; Young, H.; Chappuis, F.; Priotto, G.; Raguenaud, M.E.; Checchi, F. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans. R. Soc. Trop. Med. Hyg., 2009, 103, 280-90.
249. Giffin, B.F.; McCann, P.P.; Bitonti, A.J.; Bacchi, C.J. Polyamine depletion following exposure to DL-alpha-difluoromethylornithine both in vivo and in vitro initiates morphological alterations and mitochondrial activation in a monomorphic strain of Trypanosoma brucei brucei. J. Protozool., 1986, 33, 238-43.
250. Burri, C.; Brun, R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res., 2003, 90 Supp 1, S49-52.
251. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet, 2009, 374, 56-64.
252. Barrett, S.V.; Barrett, M.P. Anti-sleeping sickness drugs and cancer chemotherapy. Parasitol. Today, 2000, 16, 7-9.
253. Van Nieuwenhove, S.; Schechter, P.J.; Declercq, J.; Bone, G.; Burke, J.; Sjoerdsma, A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans. R. Soc. Trop. Med. Hyg., 1985, 79, 692-8.
254. Milord, F.; Pepin, J.; Loko, L.; Ethier, L.; Mpia, B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet, 1992, 340, 652-5.
255. Fairlamb, A.H. Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. Trans. R. Soc. Trop. Med. Hyg., 1990, 84, 613-7.
256. Thuita, J.K.; Karanja, S.M.; Wenzler, T.; Mdachi, R.E.; Ngotho, J.M.; Kagira, J.M.; Tidwell, R.; Brun, R. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. Acta Trop., 2008, 108, 6-10.
257. Mdachi, R.E.; Thuita, J.K.; Kagira, J.M.; Ngotho, J.M.; Murilla, G.A.; Ndung'u, J.M.; Tidwell, R.R.; Hall, J.E.; Brun, R. Efficacy of the novel diamidine compound 2,5-Bis(4-amidinophenyl)furanbis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration. Antimicrob. Agents Chemother., 2009, 53, 953-7.
258. Barker, R.H., Jr.; Liu, H.; Hirth, B.; Celatka, C.A.; Fitzpatrick, R.; Xiang, Y.; Willert, E.K.; Phillips, M.A.; Kaiser, M.; Bacchi, C.J.; Rodriguez, A.; Yarlett, N.; Klinger, J.D.; Sybertz, E. Novel Sadenosylmethionine decarboxylase inhibitors for the treatment of human African Trypanosomiasis. Antimicrob. Agents Chemother., 2009.
259. Hoet, S.; Opperdoes, F.; Brun, R.; Quetin-Leclercq, J. Natural products active against African trypanosomes: a step towards new drugs. Nat. Prod. Rep., 2004, 21, 353-64.
260. Freiburghaus, F.; Kaminsky, R.; Nkunya, M.H.; Brun, R. Evaluation of African medicinal plants for their in vitro trypanocidal activity. J. Ethnopharmacol., 1996, 55, 1-11.
261. Kodama, H.; Denso; Okazaki, F.; Ishida, S. Protective effect of humus extract against Trypanosoma brucei infection in mice. J. Vet. Med. Sci., 2008, 70, 1185-90.
262. Gehrig, S.; Efferth, T. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review). Int. J. Mol. Med., 2008, 22, 411-9.
263. Jennings, F.W.; Rodgers, J.; Bradley, B.; Gettinby, G.; Kennedy, P.G.; Murray, M. Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol. Int., 2002, 51, 381-8.
264. Jones, D.C.; Ariza, A.; Chow, W.H.; Oza, S.L.; Fairlamb, A.H. Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Mol. Biochem. Parasitol., 169, 12-9.
265. Irigoin, F.; Cibils, L.; Comini, M.A.; Wilkinson, S.R.; Flohe, L.; Radi, R. Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification. Free Radical Biol. Med., 2008, 45, 733-42.
266. Carrillo, C.; Cejas, S.; Gonzalez, N.S.; Algranati, I.D. Trypanosoma cruzi epimastigotes lack ornithine decarboxylase but can express a foreign gene encoding this enzyme. FEBS Lett., 1999, 454, 192-6.
267. Canto-Cavalheiro, M.M.; Echevarria, A.; Araujo, C.A.; Bravo, M.F.; Santos, L.H.; Jansen, A.M.; Leon, L.L. The potential effects of new synthetic drugs against Leishmania amazonensis and Trypanosoma cruzi. Microbios, 1997, 90, 51-60.
268. Bakunova, S.M.; Bakunov, S.A.; Patrick, D.A.; Kumar, E.V.; Ohemeng, K.A.; Bridges, A.S.; Wenzler, T.; Barszcz, T.; Jones, S.K.; Werbovetz, K.A.; Brun, R.; Tidwell, R.R. Structure-activity study of pentamidine analogues as antiprotozoal agents. J. Med. Chem., 2009, 52, 2016-35.
269. Mondal, D.; Singh, S.P.; Kumar, N.; Joshi, A.; Sundar, S.; Das, P.; Siddhivinayak, H.; Kroeger, A.; Boelaert, M. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl. Trop. Dis., 2009, 3, e355.
270. Cattand, P.; Jannin, J.; Lucas, P. Sleeping sickness surveillance: an essential step towards elimination. Trop. Med. Int. Health, 2001, 6, 348-61.
271. Villela, M.M.; Souza, J.M.; Melo Vde, P.; Dias, J.C. [Evaluation of the Chagas Disease Control Program and presence of Panstrongylus megistus in central-western Minas Gerais State, Brazil]. Cad. Saude Publica, 2009, 25, 907-17.